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Anita Lawitschka,1 Lynne Ball,2 Christina Peters3Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for many children with
life-threatening diseases. One of the most significant long-term complications of transplantation is chronic
graft-versus-host disease (cGVHD). Although the rates of cGVHD after HSCTare lower in the pediatric pop-
ulation than in adults, cGVHD remains a significant cause of morbidity and mortality. Medicines used to pre-
vent and treat cGVHD remain unsatisfactory, with protracted use of immune suppression necessary and high
rates of first-line treatment failure. Efforts to improve salvage treatment are urgently required. Nonpharma-
cologic strategies attempt to modulate the cellular inflammation response and possibly allow reduction or
cessation of immunosuppressive drugs. Mesenchymal stromal cells (MSC) have been shown in vitro to me-
diate a wide variety of immune responses. MSC have been used in the prophylaxis of acute GVHD (aGVHD)
and for the treatment of established steroid refractory aGVHD and, more recently, in the management of
cGVHD. Extracorporeal photochemotherapy (ECP) has shown promising efficacy in graft-versus-host
disease, and may allow a significant reduction in the use of systemic steroids and other immunosuppressants,
reducing long-term morbidity and mortality. The accumulated experience shows ECP to be well tolerated,
with no clinically significant side effects.
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stromal cellsINTRODUCTION
Chronic graft-versus-host disease (cGVHD) is
the most common late complication of allogeneic
hematopoietic stem cell transplantation (HSCT)
and has the strongest association between reduced
quality of life and impaired functional status follow-
ing HSCT in children. Active cGVHD has a signifi-
cant impact on many aspects of the overall health
status of children and adolescents. However, most
important, those successfully treated for cGVHD
do not appear to have long-term impairments [1].
Steroids and calcineurin inhibitors (CNI) are the
standard therapy for cGVHD. In addition to the
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6/j.bbmt.2011.11.001causes growth retardation, delayed puberty, chronic
organ dysfunction, and severe immunosuppression,
with the risk of life-threatening infections and the
occurrence of malignancies.
Although the clinical manifestation of cGVHD in
children is similar to that in adults, the consequences
of treatment and nonresponses are remarkably differ-
ent in a growing organism. It is essential to develop
new strategies to increase the efficiency of therapeutic
methods for cGVHD and to measure the efficacy with
validated tools.CHRONIC GVHD IN CHILDREN AND
ADOLESCENTS: THE SAME BUT DIFFERENT?
Anita Lawitschka
Pediatric cGVHD is a pleiomorphic syndrome like
in adults and diagnostic features are well published
(National Institutes of Health [NIH] consensus
development project on criteria for clinical trials in
cGVHD: I. Diagnosis and staging working group re-
port). Data specific to the pediatric population is lim-
ited. Mechanisms and manifestations appear similar,
but there are numerous child-specific considerations
that have to be taken into account. In this article,
mainly those explicit pediatric aspects will be high-
lighted.
Biol Blood Marrow Transplant 18:S74-S81, 2012 S75Nonpharmacologic Treatment of cGVHD in Children and AdolescentsAn increasing number of children receive alloge-
neic HSCT for nonmalignant diseases, such as immu-
nodeficiencies, hematologic, and metabolic disorders.
This raises 2 important issues: (1) theremay be a variety
of comorbidities because of the underlying disease,
which might alter the appearance of features of
GVHD (ie, cutaneous GVHD in Omenn syndrome
with maternal GVHD before HSCT); and (2) patients
with nonmalignant diseases do not benefit from
GVHD because they do not need any graft-versus-
malignancy effect. This should have an implication
on the GVHD therapy. The incidence of acute
GVHD (aGVHD) and cGVHD is lower (20%-50%)
than in adults, but has been increasing over the past
years because of the use of peripheral blood stem cells
(PBSCs) and unrelated and mismatched donors [2].
Meisel et al. [3] compared PBSCs to bone marrow
from unrelated donors, and although the incidence
was similar, there was more extensive cGVHD in the
PBSC group.
Child-Specific Clinical Manifestations
Skin and dermal appendages
TheGerman-Austrian-Swiss Consensus Group on
clinical practice in cGVHD published recommenda-
tions for diagnostic workup and therapy (and their
level of evidence), including pediatric aspects [1,4].
Cutaneous cGVHD is a polymorphous disease
which can involve the epidermis, the dermis and the
subcutis. Lichen planus-like changes may be present
with hyperkeratotic papules and desquamation or poi-
kiloderma with atrophy and dyspigmentation. Scle-
rotic manifestations can be either dermal or deep
subcutaneous with further fascial involvement. The
premature graying of hair, eyelashes, and eyebrows is
common and can occur even in young children. Pruri-
tus sometimes may be the first and only symptom of
cutaneous cGVHD, and flares are possibly caused by
superinfection. For estimating the body surface area
in children, the classic ‘‘rule of nines’’ has to be re-
placed by the child-specific modification. Regarding
the topical therapy, the larger skin surface area-to-
body weight ratio in children, with the increased risk
of systemic side effects of topical steroids and CNI,
is of special relevance. Pimecrolimus is a well-
established drug in the treatment of atopic dermatitis
and is occasionally used in treatment of cutaneous
manifestations of cGVHD. Phototherapy such as
narrow-band UVB, UVA1, and bath/creme PUVA
has been used in pediatric patients with promising
results. Topical therapy may be of significant advan-
tage because of the absence of systemic side effects
and to speed up local responses. Furthermore, it does
not interfere with the graft-versus-malignancy effect
and should be offered in a steroid-sparing context as
early and as often as possible.Eyes
In the report from the International Consensus
Group on clinical practice in cGVHD, recommenda-
tions for screening, diagnosis, and therapy of ocular
cGVHD are provided, including pediatric aspects [4].
Ocular cGVHD typically shows conjunctival in-
flammation leading to cicatrical conjunctivitis, kerato-
konjunctivitis, punctuate keratopathy and blepharitis.
Children rarely report dry eye symptoms; therefore, pa-
tients and parents have to be asked specific questions re-
garding these symptoms such as pain, eye-rubbing, or
secretion. Sensitivity to light can be the predominant
symptom in children. The examination in children
should be as noninvasive as possible andmay be focused
on indirect signs and symptoms of ocular surface disease
and dry eye. In the hand of a pediatric ophthalmologist,
who is experienced in GVHD, slit lamp examination
and fluorescein staining is necessary, yet the Schirmer’s
test can often be avoided.
Mouth
Regarding oral cGVHD guidelines, dealing with
diagnosticworkup, therapeutic options, and supportive
care, the International Consensus Group included
pediatric aspects. Oral manifestations are mostly mu-
cosal erythema, lichenoid hyperkeratotic changes, mu-
cosal atrophy, mucoceles and pseudomembranous
ulcers. Children rarely report dry mouth, taste alter-
ation, and difficulties swallowing. It should be kept in
mind that reduction of oral intake or the need for in-
creased drinking during eating may be the only symp-
tom. Parents and patients must be asked specific
questions regarding those symptoms. Secondary infec-
tions with viruses such as HSV1, Coxsackie, HHV6/7,
Echo-, andEnterovirus are common in children and re-
quire intensified supportive therapy. Topical therapy
with steroids or CNI increases the risk of reaching sig-
nificant systemic drug levels, especially in small infants.
Lidocainemay cause burning sensations or may reduce
the gag reflex, which may compromise swallowing in
small children.Dental healthcare teams should provide
instructions on oral prophylaxis and hygiene even in
younger children. The long-term effect of HSCT in
children on dental development may lead to distur-
bances in the dental root development, microdontia,
dental agenesis, andmalocclusions.Orthodontic appli-
ances frequently cause trauma to oral mucosa, which
may aggravate oral cGVHD. Topical fluorides should
be applied even in older children for stabilizing incipi-
ent caries [5].
Respiratory tract
There are manifold pediatric aspects in pulmonary
cGVHD, and recommendations for screening, diag-
nostic workup, and therapy are also published by the
International Consensus Group on clinical practice
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result in both obstructive and restrictive lung disease
but themost common and serious form is bronchiolitis
obliterans. Body plethysmography and measurement
of exhaled nitric oxide can be routinely applied over
the age of 5 years. Pulmonary function testing: In con-
trast to adult patients, to date no validated lung func-
tion score exists for children. With regard to
combined obstructive-restrictive lung involvement,
in children the measured effective resistance (Reff)
can be additionally used together with total lung
capacity as an indicator of restrictive ventilatory disor-
ders. Reproducible diffusion capacity is only feasible
from the age of 10 years, because an expiration time
of 10 seconds is needed. In pediatric populations,
correction for hemoglobin levels is not generally
recommended. Regarding high-resolution computed
tomography (CT), it must be kept in mind that in
children up to the age of 10 years, sedationmay be nec-
essary for the scan, making the evaluation of inspira-
tion and expiration difficult. Therefore, an early
multislice CT scan may be considered in children as
long as lung injury has not progressed, which may in-
crease the risk of sedation. In patients with clinical
signs of sinus infection and suspected sinubronchial
syndrome, a CT scan of the sinuses is suggested to ex-
plore potential foci and may also be considered even in
younger children. The use of dornase alpha inhalations
may be considered in pediatric patients with sinubron-
chial syndrome or mucous plugging. Respiratory
symptoms and pathologic findings by body plethys-
mography and high-resolution CT require further
workup by bronchoalveolar lavage to define or exclude
causative infectious agents, and biopsy may be needed
in some cases for further definitive diagnosis [6].Neurological manifestations
Neurological manifestations associated with
cGVHD comprise immune-mediated neuropathies,
myasthenia gravis and myositis and various cerebro-
vascular complications, demyelination and immune-
mediated encephalitis. Criteria for peripheral and
central nervous system (CNS) manifestations of
cGVHD, differential diagnoses, pediatric characteris-
tics, diagnostic workup, and therapeutic recommenda-
tions are provided in the report from the International
Consensus Group on clinical practice in cGVHD. In
children, the diagnosis of cGVHD of the CNS should
be considered with great caution because (1) the devel-
oping CNS in childhood is particularly vulnerable to
the myeloablative therapy, (2) viral infections or reac-
tivation of common viruses appear to bemore frequent
in pediatric patients than in adults, (3) in children
transplanted for neurometabolic diseases, CNS pro-
cesses may be difficult to distinguish from the disease
progression of the underlying disease [7].Gastrointestinal tract
Many gastrointestinal (GI) symptoms like diarrhea,
nausea, abdominal pain and crampingmay be related to
GVHD but chronic GI GVHD mostly effects the oe-
sophagus leading to desquamation and submucosal fi-
brosis with possible strictures. Other differential
diagnoses, for example, aGVHD, drug-related side ef-
fects (eg, mycophenolate-mofetile), pancreatic insuffi-
ciency, and dysmobility have to be ruled out [8].
Infections (eg, adenovirus), lactose intolerance, and
protein-losing enteropathy should be excluded, espe-
cially in children. Weight loss and a reduced body
mass index are clinically significant issues andmay con-
tribute to increased mortality [9]. On the other hand,
feeding and nutrition is a common field of interaction
between caregivers and children. Therefore, early co-
operation with a pediatric nutritionist is required, and
attention to fluid status and electrolyte/protein man-
agement is essential [10].
Liver
As in adults, the typical appearance of hepatic
cGVHD is obstructive jaundice, but hepatitic
cGVHD with isolated elevation of liver transaminases
is also seen in children [11]. Diagnostic workup has to
exclude (1) infection by hepatitis virus A, B, C, ABV,
CMV, ADV,HHV6/7, and VZV, and (2) drug toxicity
(ie, fluconacole, CNIs).
Vulvovaginal
Vulvavaginal cGVHD can be very subtle with of-
ten patchy erythema, lichen planus-like features, scar-
ring and stenosis. Distinctive signs like erosions,
fissures and ulcers may be attributable to other causes
including infections and drug-related side effects. The
risk of under diagnosis may be higher because symp-
toms such as vulvovaginal irritation, dryness, and
pain are rarely communicated by children, and self-
examination is often lacking. Therefore, an extensive
clinical status including Tanner staging and inspection
of external genitalia seems crucial in our experience.
An appropriate patient history should include hygiene
practices, urinary and intestinal habits, or disturbances
and pretreatments. The possibility of a very late onset
of symptoms, with the risk of vaginal obstruction and
hematocolpos at the time point of menarche, pinpoints
the importance of long-term follow-up. Underlying
diseases, such as Fanconi anemia, with an increased
risk of secondary malignancies have to be taken into
account. The referral to a pediatric experienced gyne-
cologist is highly recommended.
Because of anatomic reasons, lack of estrogeniza-
tion, and behavioral factors (eg, frequent contact with
irritants such as bubble bath, wet wipes, and soaps),
the pediatric vulvovagina is particularly susceptible to
irritation and infection. Patients after HSCT may be
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system and the atrophy of vaginal epithelium with less
protective mucous. In girls with cGVHD, Cushing
syndrome, and obesity, proper vulvar hygiene is even
more important. Concomitant infections (bacterial,
fungal, and viral) and pinworms have to be ruled out.
Vaginal swabs for cultures and virus isolation should
be done trans-hymenally from the lower vagina.
Metabolic bone diseases
Skeletal complications like osteoporosis and avas-
cular necrosis are commonly seen after HSCT in chil-
dren and adolescents and the Consensus Group aimed
to give recommendations for screening and prevention
of metabolic bone diseases, for diagnosis, and thera-
peutic options [12].
Regarding the follow-up of children and adoles-
cents, measurements of bone mineral density by
dual-energy X-ray absorptiometry should use the
Z-score, which is adjusted to age, gender, and body
size. Patients with older age at HSCT, total body
irridiation, prolonged immunosuppressive treatment,
inactivity, and hypogonadism are at risk for osteoporo-
sis and avascular necrosis. Supportive care includes
optimized nutritional intake, treatment of hypogonad-
ism, vitamin D and calcium supplementation, and
weight-bearing exercises. The use of biphosphonate
therapy in children remains controversial because of
inadequate long-term efficacy and safety data.
Conclusion
In contrast to adults, different consequences arise in
children, because their organ system is still developing:
1. Both organ function and development may be in-
hibited by cGVHD and its treatment, and there
seems to be a high incidence and variety of late ef-
fects in pediatric cGVHD patients. Thus, the toxic-
ity profiles of different treatment options are
substantial and considerations must evaluate the
impact on growth, bonemetabolism, hormonal bal-
ance, nutrition, organ function and development,
and immunoreconstitution [13].
2. The consequences of long-term steroid use in chil-
dren and organ-toxic side effects of CNI are well
described. Therefore, topical therapy should be of-
fered as early and as often as possible [14].
3. As infectious complications are of special concern,
treatment modalities such as extracoreporeal pho-
tochemotherapy (ECP) or mesenchymal stromal
cells (MSC), which are on the one hand steroid
sparing, and on the other hand are not associated
with an increased risk for infectious morbidity and
mortality, are of particular interest.
To enhance pediatric issues of cGVHD, interna-
tional cooperation and networking are of utmost
importance.MSCs
Lynne Ball
Immunomodulatory properties of MSCs
Experimental models suggest that MSCs have
potent immune-modulatory effects, primarily through
the inhibition of effector functions, thus offering
a promising option for treating immune-mediated dis-
orders includingGVHDandautoimmunediseases [15].
MSCs are poor antigen-presenting cells and do not
express major histocompatibility complex class II or
costimulatory molecules. Human BM stromal cells
suppress T-lymphocyte proliferation induced by cellu-
lar or nonspecific mitogenic stimuli and inhibit the
response of na€ıve and memory antigen-specific T cells
to their cognate peptide [16]. Accordingly, expanded
MSCs do not stimulate T cell proliferation in mixed
lymphocyte reactions and are able to down-regulate
allo-reactive T cell responses when added to mixed
lymphocyte cultures [17]. However, in an immuno-
competent hostMSCs have been shown to elicit an im-
mune response (in the context of a murine model of
reduced intensity allogeneic stem cell transplantation)
[18]. Human MSCs altered the cytokine secretion
profile of dendritic cells (DCs), naive and effector T
cells (T helper 1 [T(h)1] and T(h)2), and natural killer
(NK) cells to induce a more anti-inflammatory or tol-
erant phenotype [19]. Various interactions mediating
suppression of T cell proliferation have been pro-
posed, but as yet the mechanisms remain unclear.
What is evident is that most studies demonstrate that
soluble factors are involved, as the separation of MSC
and peripheral blood mononuclear cells by trans-well
permeable membrane does not prevent the inhibition
of proliferation [20]. MSCs are capable of inhibiting
the maturation of monocytes into DCs, and of skewing
mature DCs to an immature DC state [21].
MSCs up-regulate CD41CD251 Fox P31 cells
(T regulatory immunophenotype), albeit their deple-
tion has no effect on the inhibition of T cell prolifera-
tion by MSC.
At low NK-to-MSC ratios, MSCs alter the
phenotype of NK cells and suppress proliferation,
cytokine secretion, and cytotoxicity against HLA-class
I-expressing targets [22]. Some of these effects require
cell-to-cell contact, whereas others are mediated by
soluble factors, including transforming growth factor-
b1 and prostaglandin E2, suggesting the existence of
diverse mechanisms for MSC-mediated NK-cell sup-
pression. On the other hand, MSCs are susceptible to
lysis by activatedNK cells via NKG2D [23]. The inter-
action between MSCs and in vitro B cell proliferation,
differentiation, and survival is still unclear. However,
as T cells orchestrate B cell function, it is likely that
the ultimate effect of MSCs on B cells is influenced
in vivo by MSC inhibition on T cells [24].
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Infusion of allogeneic MSCs ameliorated lethal
GVHD in mice receiving haploidentical HSCT, but
only whenMSCs where administered early and repeat-
edly after transplantation [25].
Recently, the effects of MSCs have been reported
in animal models of autoimmunity, such as ameliora-
tion of experimental autoimmune encephalitis in amu-
rine model, raising the possibility of MSC use in
autoimmune diseases [26]. In a collagen-induced ar-
thritis mice model, a worsening of disease was seen af-
ter administration of an allogeneic MSC cell line,
albeit other murine studies using allogeneic MSC con-
versely showed demonstrable clinical improvement.
Clinical results
Animal models may not predict the clinical situa-
tion as the immune modulatory mechanisms between
species (eg, murine and human MSCs) may differ.
Clinical application of ex vivo expanded MSC therapy
in the pediatric HSCT setting has to date exploited
their potential immune modulatory properties as well
as their abilities to support HSC proliferation.
Chronic GVHD
The use of MSC in intractable cGVHD has been
recently reported. The first published report was of
a temporary response to MSC infusion in a patient
with hepatic cGVHD. The same report suggest that
MSC may be useful in the treatment of scleroderma-
tous cGVHD [27].
Four patients were included and received MSC by
an intraosseal route. The dose administered was 1-2
106/kg recipient weight with 4 to 8 infusions being
administered. All patients showed significant clinical
improvement within the first 2 weeks following initial
MSC infusions. All patients had been transplanted for
acute leukemia, and at a median follow-up of 14.1
months (range: 4.6-23) no relapses had occurred.
Flow cytometric analysis of peripheral blood
inteferon-gamma, interleukin (IL)-2-, IL-10-, and
IL-4- producing cells were monitored before and after
MSC infusion. Pre-MSC infusion, there was a shift
toward Th2 type cells (ie, higher proportion of
IL-10 and IL-4 compared with inteferon-gamma and
IL-2-producing cells). After repeated MSC infusions,
the proportion of these cells was reversed, that is, a shift
to Th1 subset. The authors suggest this is a direct
action of in vivo MSC infusion immunomodulation
paralleling the clinical response [28].
A recent pilot study was undertaken in adult
patients with established cGVHD unresponsive to
standard immunosuppression at 1 month from com-
mencement or with progression after at least 2 weeks
from the start of immunosuppression. A median dose
of 0.6  106/kg recipient weight was administered
(range: 0.23-1.42). The median number of dosesadministered was 2 infusions (range: 1-5), with the
median duration between infusions of 188 days (range:
13-944). A response rate (either complete or partial
resolution) of 74% was observed and immunosupres-
sion could be tapered successfully in one-half of these
patients and discontinued in 5, with a median immu-
nosupression duration of 324 days (range: 200-550).
The median response time from the first infusion of
MSC to the best documented response was 233 days
(range: 81-761). Response to MSC was organ depen-
dent with mucosal lesions responding better (100%,
n 5 16) compared with ophthalmologic (35%,
n5 8), hepatic (90%, n5 10) and gastrointestinal tract
(90%) complications. Three patients who developed
pulmonary cGVHD after treatment with MCS had
improved their initial clinical symptoms. Patients
responding to MSC infusion had significant increases
in CD31 and CD42 T cells, and a decrease of CD31
CD82 T cells at 3 months postinfusion compared
with those patients without any clinical response. No
changes in circulating CD41251 or CD81 CD251
T cells were observed. In addition CD51 CD191 B
cell subsets increased, and CD52 CD191 B cells de-
creased in the responsive group [29].
Conclusion
MSC transplantation offers potential for the future,
and the results of phase I/II studies now pave the way
for randomized studies in the future. Developments
within the allogeneic transplant setting, further under-
standing of the properties of expanded MSCs, and
exploiting the immune modulatory properties of
MSCs offers new potential modalities of treatments
for pediatric cGVHDrefractory to standard treatments.
Although immediate safety issues have been
addressed, the long-term follow-up of patients treated
withMSC is required. The issues of dosage and timing
as well as efficacy of these novel therapies need to be
addressed. Biological studies should be incorporated
in future clinical applications to increase the under-
standing of the functional properties of MSCs relevant
to their role in modulating alloreactivity.
The development of an implementation of
randomized multicenter studies involving cellular
therapies presents significant challenges, which need
to be addressed before the role of MSCs can be fully
elucidated.ECP
Christina Peters
ECP involves the collection of blood MNCs by
cytapheresis. The cells are exposed to a photosensitiz-
ing drug, 8-methoxypsoralen, andUVA light, and then
returned to the patient. The mechanism of action of
ECP has not yet been fully characterized. However,
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immune effects, that is, the up-regulation of an antitu-
mor immune response to treat a malignant disorder
such as cutantous T cell lymphoma and the down-
regulation of T cell-mediated autoimmune and
alloimmune disorders [30]. Very recently, it has been
reported that the proportion of immature CD191
CD212 B lymphocytes may be correlated with ECP
response in cGVHD [31]. In GVHD, therefore,
ECP may act selectively on the sensitized and active
cells, thus reducing the graft-versus-host reaction
without inhibiting the remaining naive and memory
lymphocytes that are crucial for normal immune re-
sponses [32].
In adult patients, ECP has been shown to be effi-
cient in the treatment of aGVHD and cGVHD, with
response rates ranging from 50% to 71% [33,34].
Also, in children, the authors report a response rate
to ECP in steroid refractory cGVHD from 33% to
93%. The 5-year overall survival was 96% for ECP
responders versus 58% for nonresponders (P 5 .04)
[35,36]. Most published reports on pediatric ECP are
either case studies or small, single-center, historic
series, and thus the main difficulties in interpreting
efficacy and toxicity are marked heterogeneity in
patient enrollment, inconsistency in the intervals
between onset of disease and the start of ECP, and
no standardization of the definition of treatment
responses. Perotti et al. [35] performed a longitudinal
study on factors influencing the response and survival
in pediatric patients undergoing ECP for GVHD.
One of the major findings was that in cGVHD,
69.5% of patients responded and at day 30, the overall
median percentage change in steroid usage from base-
line was 247.4%. Decrease of steroid dose at 30 days
was associated with survival; for each 1 mg/kg reduc-
tion, the hazard ratio was 2.2. To permit tapering or
sparing immunosuppression, in particular, corticoste-
roids, is of great relevance for children, not only for re-
ducing acute side effects but also for improving quality
of life [37]. Similar findings were described by Kanold
et al., who describe a dramatic improvement in 4 of 6
patients suffering from chronic hepatic GVHD, and
7 of 9 patients with gastrointestinal GVHD showed
complete recovery from their digestive symptoms after
initiation of ECP. Kanold et al. elaborated clinical
practice guidelines based on field experience and
review of the literature, and describe the following
indications and eligibility criteria:
1. Severe GVHD not responding to steroid treat-
ment. In these patients, ECP is combined with
a second-line immunosuppressive therapy.
2. Severe GVHD responding to ‘‘conventional treat-
ment’’ but with intolerable treatment-related side
effects. ECP is combined with the second-line
agents to allow rapid steroid tapering.3. Patients who have been unsuccessfully treated with
more than 3 lines of conventional immunosuppres-
sive therapy and are resistant or dependent and/or
patients with late-stage disease.
4. Children with limited cGVHD, regardless of other
therapies deployed [37a].
Apheresis in children presents specific difficulties
and complications (vascular access, extracorporeal
volume, metabolic and hematologic problems, and
psychologic tolerance).
Different ECP techniques are currently used in
children: either a standard cell separator for MNC
collection and UVA irradiation performed with
a ‘‘stand-alone’’ irradiator in the laboratory (COBE
Spectra 1 UV-MATIC) or an automated single-
device collection and irradiation system (UVAR-
XTS, Therakos, Exton, PA). Similar efficacy figures
have been reported with both techniques, but no
head-to-head comparison has been published. In the
pediatric context, the COBE Spectra and UV-
MATIC systems offer several advantages over the
Therakos system: (1) the extracorporeal volume of
the COBE Spectra AutoPBSC (164 mL) or manual
collection program (287 mL) compares favorably
with that of the Therakos device, which varies from
300 to 600 mL depending on the patient’s Hct; (2)
the COBE device allows a better MNC collection in
less time, which is an important factor in terms of
psychological tolerance; and (3) the COBE Spectra
makes it possible to reduce and manually control the
final collection volume [38]. Because of the volume
issues, the hemoglobin count is a critical criterion for
starting MNC collection, and it has to be defined
whether simple transfusion, RBC priming of the
circuit, or no intervention is required.
Both the optimal timing schedule and the duration
of ECP have yet to be clearly established. The sched-
ules currently used are either empiric or related to
schedules that have been used for the treatment of
lymphoma. However, the intervals between ECP
sessions became shorter for patients recently enrolled
compared with patients enrolled at the beginning of
the 1990s [39]. For aGVHD, there is a certain degree
of consensus, and most centers start with intensive
twice-weekly or thrice-weekly treatment schedules,
which are intuitively appropriate for acute disease.
Duzovali and Chan [40] recently proposed an intensive
ECP schedule in pediatric patients with steroid-
resistant or steroid-dependent cGVHD. Although
they could not demonstrate the impact of ECP inten-
sity on response rates, this intensive treatment sched-
ule of up to 5 times a week appeared well tolerated.
Most authors recommend continuing ECP until
maximum response is achieved, followed by an individ-
ual progressive tapering of therapy. For small children
and critically ill patients, a minibuffy coat
S80 Biol Blood Marrow Transplant 18:S74-S81, 2012A. Lawitschka et al.photopheresis was developed and showed comparable
outcomes to the classical procedures. The offline
systems allow leukapheresis and UVA-irradiation
from 12 kg BW to . 100 kg, the Mini-ECP system
could be used in children . 4 kg BM. High billirubin
level have no influence to successfully perform an ECP
with an inline or offline systems. However, for the
mini-ECP method there might occure problems
to separate mononuclear cells by a Ficoll-gradient
[41-43].
ECP-associated complications are usually mild
(during the procedure: chills, mild abdominal pain,
headache, and rarely hypotension or metabolic imbal-
ance; after MNC reinfusion: fever—most often associ-
ated with intravenous access infections). Considering
that most patients receive multiple lines of immuno-
suppression, it is impossible to discriminate the effects
of each particular treatment, but the frequency of virus
reactivations did not appear to be increased by the ad-
dition of ECP treatment. Moreover, ECP in patients
with GVHD does not result in an increased incidence
of malignant relapse, and patients undergoing long-
term ECP therapy for CTCL and scleroderma do
not develop the infections or secondary malignancies
that are associated with conventional immunosuppres-
sants. Patients receiving ECP respond normally to new
immune challenges such as exposure to pathogens or
vaccines [44]. Thus, there are no arguments to suggest
that ECP acts as an immunosuppressive therapy.
In conclusion, ECP as a salvage therapy for
cGVHD results in high response rates in cutaneous
and extracutaneousmanifestations.The overall survival
is significantly longer in ECP responders compared
withECPnonresponders.However, the association be-
tween dose intensity and response is not yet clearly
shown. The safety profile is excellent, even in small
children, and the procedure is well tolerated within an
experienced and well-trained pediatric setting. In addi-
tion to the steroid-sparing effect, the reduction of phar-
macologic immunosuppressive medicines contributes
to a possibly augmented infection control and graft-
versus-malignancy effect.ACKNOWLEDGMENTS
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